沃华医药：2025年净利润同比预增119.76%—215.9%

Core Viewpoint - Wohuah Pharmaceutical (002107) expects a net profit attributable to shareholders of 80 million to 115 million yuan for 2025, representing a year-on-year growth of 119.76% to 215.90% [1] Financial Performance - The company has implemented a strategy termed "one reduction, three increases" (reducing costs, increasing sales, increasing efficiency, and increasing cash flow) [1] - Effective cost control has been achieved during the reporting period [1] Market Strategy - Marketing reforms have shown solid results, allowing the company to adapt to the competitive landscape following the entry of Wohuah's Xin Keshun tablets into centralized procurement [1] - A trend of exchanging price for volume has begun to emerge in the market [1]